熊去氧胆酸联合疏肝利胆汤加减治疗早、中期原发性胆汁性肝硬化的效果
|
摘要
目的探讨熊去氧胆酸联合疏肝利胆汤加减治疗早、中期原发性胆汁性肝硬化(PBC)的效果。方法将我院102例早、中期PBC患者随机分为对照组(熊去氧胆酸)和观察组(熊去氧胆酸联合疏肝利胆汤加减),各51例。比较两组的治疗效果。结果观察组的显效率、治疗总有效率、血清VEGF、ALP、GGT、ALT、AST、TBIL、HA、Ⅳ-C和PC-Ⅲ水平均优于对照组(P<0.05)。结论熊去氧胆酸联合疏肝利胆汤加减治疗早、中期PBC效果肯定,值得应用推广。
Objective To investigate the effect of ursodeoxycholic acid combined with modified Shugan Lidan decoction in the treatment of early and middle stage primary biliary cirrhosis(PBC). Methods A total of 102 patients with early and middle stage PBC in our hospital were randomly divided into control group(ursodeoxycholic acid) and observation group(ursodeoxycholic acid combined with modified Shugan Lidan decoction), with 51 cases in each group. The treatment effects of the two groups were compared. Results The effectiveness rate and total effective rate of treatment, serum levels of VEGF,ALP, GGT, ALT, AST, TBIL, HA, IV-C and PC-Ⅲ in the observation group were better than those in the control group(P<0.05). Conclusion Ursodeoxycholic acid combined with modified Shugan Lidan decoction has definite effect on PBC in the early and middle stages, which is worthy of application and promotion.
Objective To investigate the effect of ursodeoxycholic acid combined with modified Shugan Lidan decoction in the treatment of early and middle stage primary biliary cirrhosis(PBC). Methods A total of 102 patients with early and middle stage PBC in our hospital were randomly divided into control group(ursodeoxycholic acid) and observation group(ursodeoxycholic acid combined with modified Shugan Lidan decoction), with 51 cases in each group. The treatment effects of the two groups were compared. Results The effectiveness rate and total effective rate of treatment, serum levels of VEGF,ALP, GGT, ALT, AST, TBIL, HA, IV-C and PC-Ⅲ in the observation group were better than those in the control group(P<0.05). Conclusion Ursodeoxycholic acid combined with modified Shugan Lidan decoction has definite effect on PBC in the early and middle stages, which is worthy of application and promotion.
引文
[1]李绍祥,李亚松,李浩然,等.原发性胆汁性肝硬化的发病机制研究进展[J].北京医学,2014,36(6):471-473.
[2]韩英,朱疆依.难治性原发性胆汁性肝硬化的治疗[J].中华肝脏病杂志,2012,20(5):330-332.
[3]邱德凯,马雄.自身免疫性肝病基础与临床[M].上海:上海科学技术出版社,2006:110-111,191-192.
[4]黄敏,陈继红.原发性胆汁性肝硬化和自身免疫性肝炎的临床特点分析[J].医学研究杂志,2017,46(2):86-89.
[5]徐琼,张锋.疏肝利胆通络解毒方联合熊去氧胆酸治疗原发性胆汁性肝硬化的疗效分析[J].中国中医药科技,2016,23(6):724-726.
[6]HONDA A,IKEGAMI T,NAKAMUTA M,et al.Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid[J].Hepatology,2013,57(5):1931-1941.
[7]任朦,郑亚江,祝峻峰.原发性胆汁性肝硬化中医辨证分型[J].吉林中医药,2016,36(7):678-681.
[8]许雪莲.基于数据挖掘的金实教授诊治慢性肝病的经验研究[D]南京:南京中医药大学,2014.
[9]刘翔.当归芍药散联合异甘草酸镁治疗原发性胆汁性肝硬化的疗效观察及对血清MMP2、MMP9、VEGF水平的影响[J].中国中西医结合消化杂志,2018,26(6):524-528,534.
[2]韩英,朱疆依.难治性原发性胆汁性肝硬化的治疗[J].中华肝脏病杂志,2012,20(5):330-332.
[3]邱德凯,马雄.自身免疫性肝病基础与临床[M].上海:上海科学技术出版社,2006:110-111,191-192.
[4]黄敏,陈继红.原发性胆汁性肝硬化和自身免疫性肝炎的临床特点分析[J].医学研究杂志,2017,46(2):86-89.
[5]徐琼,张锋.疏肝利胆通络解毒方联合熊去氧胆酸治疗原发性胆汁性肝硬化的疗效分析[J].中国中医药科技,2016,23(6):724-726.
[6]HONDA A,IKEGAMI T,NAKAMUTA M,et al.Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid[J].Hepatology,2013,57(5):1931-1941.
[7]任朦,郑亚江,祝峻峰.原发性胆汁性肝硬化中医辨证分型[J].吉林中医药,2016,36(7):678-681.
[8]许雪莲.基于数据挖掘的金实教授诊治慢性肝病的经验研究[D]南京:南京中医药大学,2014.
[9]刘翔.当归芍药散联合异甘草酸镁治疗原发性胆汁性肝硬化的疗效观察及对血清MMP2、MMP9、VEGF水平的影响[J].中国中西医结合消化杂志,2018,26(6):524-528,534.